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LETTER
RESEARCH LETTER
Dupilumab reduces absenteeism in
patients with moderate to severe
atopic dermatitis: Pooled results
from the LIBERTY AD SOLO clinical
trials
To the Editor: Moderate to severe atopic dermatitis
(AD) negatively affects daily functioning, quality of
life (QoL), and work productivity,1 more so for
patients with inadequate symptom control.2 The
SOLO 1 and 2 phase 3 clinical trials showed that
dupilumab versus placebo significantly improved
signs, symptoms, and QoL in patients with moderate
to severe AD, with an acceptable safety profile.3 This
study evaluated the impact of dupilumab on work/
school productivity using a pooled analysis of the
SOLO trials.
The designs and primary findings from the SOLO
trials have been reported previously.3 Adults with
moderate to severe AD inadequately controlled by
topical treatments received dupilumab (300 mg sub-
cutaneously weekly or every 2 weeks) or placebo
(subcutaneously weekly) over 16 weeks. We evalu-
ated the mean number of missed days from work/
school (absenteeism) and related costs in patients
reporting full-time employment or school ($4 days/
week) and in patient subgroups categorized by
baseline symptom severity, including Investigator’s
Global Assessment of 3 or 4, Peak Pruritus Numerical
Rating Scale score of less than 7 or 7 or greater, and
Dermatology Life Quality Index of less than or equal
to 10 or greater than 10. Duration-adjusted annual-
ized absenteeism rate at week 16 was estimated
using Poisson regression with treatment, region, and
baseline Investigator’s Global Assessment strata as
fixed factors and the log value of assessment days up
to weeks 4, 8, 12, or 16 as offset variables. Annual
productivity costs for a hypothetical cohort of 10,000
treated patients were calculated using daily labor or
employee compensation costs (2018 European
Union4 and US5 rates).
Most (72%) SOLO participants reported full-time
work/school commitments, with similar baseline char-
acteristics among groups (Table I). Absenteeism rates
first collected at week 4 showed a difference between
dupilumab and placebo groups (mean [standard error]
missed days per patient-year: placebo, 12.1 [0.76];
dupilumab every 2 weeks, 5.4 [0.49]; dupilumab every
week, 7.0 [0.55]). Annualized absenteeism rates by
week 16 were significantly lower with dupilumab
(Table II), with 5.6 (every 2 weeks) and 4.4 (every
week) fewer missed days per patient-year versus
placebo. This finding persisted in analyzed subgroups,
with greater reductions in missed days among those
with greater baseline AD severity (Table II). Reduced
Table I. Baseline characteristics of SOLO participants with full-time work/school commitments (full analytic
sample)
Baseline characteristic Placebo (n = 319)
Dupilumab 300 mg
every 2 weeks (n = 332)
Dupilumab 300 mg
every week (n = 346)
Age, y, median (Q1-Q3), range 35 (26-46), 18-64 35 (26-44), 18-77 36 (26-47), 18-80
Male sex, n (%) 185 (58) 206 (62) 228 (66)
BMI, kg/m2, median (Q1-Q3) 25.1 (22.6-29.0) 25.2 (22.7-28.7) 25.3 (22.1-28.7)
Duration of AD, y, median (Q1-Q3) 27 (19-38) 26 (18-38) 25 (17-37)
Total EASI, median (Q1-Q3) 29 (22-42) 29 (21-40) 29 (22-43)
IGA score, n (%)
3 (moderate) 173 (54.2) 174 (52.4) 180 (52.0)
4 (severe) 146 (45.8) 158 (47.6) 166 (48.0)
Weekly averaged Peak Pruritus NRS
score, median (Q1-Q3)
7.7 (6.4-8.7) 7.7 (6.3-8.8) 7.6 (6.3-8.6)
DLQI, median (Q1-Q3) 14 (8-20) 14 (9-20) 15 (9-21)
AD, Atopic dermatitis; BMI, body mass index; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; IGA, Investigator’s
Global Assessment; NRS, Numerical Rating Scale; Q1, quartile 1; Q3, quartile 3.
ª 2020 by the American Academy of Dermatology, Inc. Published by
Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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absenteeism resulted in lower productivity costs with
dupilumab. Annual productivity costs avoided for the
hypothetical cohort (based on annualized reduction of
5.6 days per patient-year with dupilumab every
2 weeks) were US$16.2 million (United States), V15.3
million (Germany), V14.1 million (France), V12.6
million (Italy), £10.1 million (United Kingdom), and
V9.5 million (Spain).
Dupilumab, thus, provided significant reductions
in work/school absenteeism with associated cost
savings versus placebo. Initial absenteeism and
annualized reductions were greater with more se-
vere AD and worse QoL at baseline.
Our findings may be different from a real-world
population because of the controlled nature of
clinical trials. The 16-week duration-adjusted anal-
ysis was extrapolated to annual estimates; the effect
of long-term treatment would require further inves-
tigation. There was no baseline assessment before
treatment administration, with absenteeism rates first
being collected at week 4; nonetheless, subsequent
productivity outcomes were markedly different.
Absenteeism rates were pooled across work/school
settings and countries, with inherent variability that
may affect generalizability.
The productivity burden of AD on patients
with inadequately controlled disease is substan-
tial but may be ameliorated with dupilumab
treatment.
The authors would like to thank Qiuyue Chen for
contributions to this work. Medical writing/editorial
assistance was provided by Grace Richmond, PhD, of
Excerpta Medica, funded by Sanofi Genzyme and Regen-
eron Pharmaceuticals, Inc.
Table II. Duration-adjusted annualized absenteeism rate* per patient-year by baseline disease severity at
week 16
Placebo
Dupilumab 300 mg
every 2 weeks
Dupilumab 300 mg
every week
Full analytic sample
n 319 332 346
Absenteeism rate, days per patient-year (SE) 9.1 (0.34) 3.5 (0.20)y 4.7 (0.23)y
95% CI 8.4-9.8 3.1-3.9 4.3-5.2
IGA score of 3
n 173 174 180
Absenteeism rate, days per patient-year (SE) 6.4 (0.36) 3.5 (0.26)y 3.6 (0.27)y
95% CI 5.7-7.1 3.0-4.0 3.1-4.1
IGA score of 4
n 146 158 166
Absenteeism rate, days per patient-year (SE) 11.3 (0.55) 3.2 (0.28)y 5.7 (0.37)y
95% CI 10.2-12.4 2.6-3.7 5.0-6.4
Peak pruritus NRS of\7
n 100 112 114
Absenteeism rate, days per patient-year (SE) 5.0 (0.46) 1.3 (0.20)y 3.2 (0.32)z
95% CI 4.1-6.0 0.9-1.7 2.5-3.8
Peak pruritus NRS of $7
n 219 219 230
Absenteeism rate, days per patient-year (SE) 11.0 (0.44) 4.8 (0.29)y 5.7 (0.31)y
95% CI 10.1-11.8 4.2-5.4 5.1-6.3
DLQI of #10
n 112 108 111
Absenteeism rate, days per patient-year (SE) 1.7 (0.26) 0.6 (0.14)y 0.9 (0.18)z
95% CI 1.2-2.2 0.3-0.8 0.5-1.2
DLQI of[10
n 207 224 235
Absenteeism rate, days per patient-year (SE) 13.0 (0.49) 5.0 (0.29)y 6.5 (0.33)y
95% CI 12.0-13.9 4.4-5.5 5.9-7.2
Higher scores indicate worse signs (IGA), symptoms (Peak Pruritus NRS), and negative impact on quality of life (DLQI).
CI, Confidence interval; DLQI, Dermatology Life Quality Index; IGA, Investigator’s Global Assessment; NRS, Numerical Rating Scale; SE,
standard error.
*Estimated using Poisson regression with treatment, region, and baseline IGA strata as fixed factors and the log value of assessment days up
to weeks 4, 8, 12, or 16 used as offset variables.
yP\ .0001 versus placebo.
zP\ .01 versus placebo.
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